Review of pharmacogenomics of psychiatric comorbidities in autism spectrum disorder

被引：0

作者：

Alvarez, Aida ^{[1
]}

Bote, Valentin ^{[1
]}

Lamborena, Cristina ^{[1
]}

Medina, Raquel ^{[1
]}

Serra-LLovich, Alexandre ^{[2
]}

Hervas, Amaia ^{[1
]}

Arranz, Maria J. ^{[2
]}

机构：

[1] Hosp Univ Mutua Terrassa, Dept Child & Adolescent Psychiat, Barcelona, Spain

[2] Fundacio Docencia & Recerca Mutua Terrassa, Res Lab Unit, Terrassa, Spain

来源：

PHARMACOGENOMICS | 2023年

关键词：

antidepressants; autism spectrum disorder; personalized medicine antipsychotic; pharmacogenetics; review; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PSYCHOTROPIC MEDICATION USE; SEROTONIN TRANSPORTER GENE; CYP2D6; POLYMORPHISM; DISRUPTIVE BEHAVIOR; RECEPTOR GENE; CHILDREN; ADOLESCENTS; EFFICACY; RISPERIDONE;

D O I：

10.2217/pgs-2023-0134

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Approximately 70% of individuals diagnosed with autism spectrum disorder (ASD) receive at least one psychotropic medication to treat comorbidities. However, the response to treatment with these drugs is far from satisfactory, with 30-50% of treated patients not responding adequately or developing severe and long-lasting side effects. There is strong evidence of the clinical utility of pharmacogenetics for the personalization of antipsychotic and antidepressant treatments in adult populations. However, the use of pharmacogenetic interventions for the personalization of treatment in ASD populations is minimal. The aim of this review is to summarize the findings of pharmacogenetic studies conducted in subjects with ASD and illustrate their utility in the personalization of treatment with psychoactive drugs in this population group.

引用

页码：781 / 791

页数：11

共 83 条

[1] Psychotropic prescribing rates and pharmacogenomic testing implications for autism in the Canadian primary care sentinel surveillance network [J].

Ahmed, Zeeshan ;

Hao, Sylvia ;

Williamson, Tyler ;

McMorris, Carly A. ;

Bousman, Chad A. .

PHARMACOGENETICS AND GENOMICS, 2022, 32 (03) :94-100

[2]

Altar C Anthony, 2015, Mol Neuropsychiatry, V1, P145, DOI 10.1159/000430915

[3] A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex [J].

Antaki, Danny ;

Guevara, James ;

Maihofer, Adam X. ;

Klein, Marieke ;

Gujral, Madhusudan ;

Grove, Jakob ;

Carey, Caitlin E. ;

Hong, Oanh ;

Arranz, Maria J. ;

Hervas, Amaia ;

Corsello, Christina ;

Vaux, Keith K. ;

Muotri, Alysson R. ;

Iakoucheva, Lilia M. ;

Courchesne, Eric ;

Pierce, Karen ;

Gleeson, Joseph G. ;

Robinson, Elise B. ;

Nievergelt, Caroline M. ;

Sebat, Jonathan .

NATURE GENETICS, 2022, 54 (09) :1284-+

[4] Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers [J].

Arranz, Maria J. ;

Salazar, Juliana ;

Bote, Valentin ;

Artigas-Baleri, Alicia ;

Serra-LLovich, Alexandre ;

Trivino, Emma ;

Roige, Jordi ;

Lombardia, Carlos ;

Cancino, Martha ;

Hernandez, Marta ;

Cendros, Marc ;

Duran-Tauleria, Enric ;

Maraver, Natalia ;

Hervas, Amaia .

PHARMACEUTICS, 2022, 14 (05)

[5] Pharmacogenetics of antipsychotics: Clinical utility and implementation [J].

Arranz, Maria J. ;

Salazar, Juliana ;

Hernandez, Marta H. .

BEHAVIOURAL BRAIN RESEARCH, 2021, 401

[6] A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments [J].

Arranz, Maria J. ;

Gonzalez-Rodriguez, Alex ;

Perez-Blanco, Josefina ;

Penades, Rafael ;

Gutierrez, Blanca ;

Ibanez, Laura ;

Arias, Barbara ;

Brunet, Merce ;

Cervilla, Jorge ;

Salazar, Juliana ;

Catalan, Rosa .

TRANSLATIONAL PSYCHIATRY, 2019, 9 (1)

[7] Food Selectivity in Children with Autism Spectrum Disorders and Typically Developing Children [J].

Bandini, Linda G. ;

Anderson, Sarah E. ;

Curtin, Carol ;

Cermak, Sharon ;

Evans, E. Whitney ;

Scampini, Renee ;

Maslin, Melissa ;

Must, Aviva .

JOURNAL OF PEDIATRICS, 2010, 157 (02) :259-264

[8] Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics [J].

Beunk, Lianne ;

Nijenhuis, Marga ;

Soree, Bianca ;

de Boer-Veger, Nienke J. ;

Buunk, Anne-Marie ;

Guchelaar, Henk Jan ;

Houwink, Elisa J. F. ;

Risselada, Arne ;

Rongen, Gerard A. P. J. M. ;

van Schaik, Ron H. N. ;

Swen, Jesse J. ;

Touw, Daan ;

van Westrhenen, Roos ;

Deneer, Vera H. M. ;

van der Weide, Jan .

EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 (03) :278-285

[9] Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder [J].

Bishop, Jeffrey R. ;

Najjar, Fedra ;

Rubin, Leah H. ;

Guter, Stephen J. ;

Owley, Thomas ;

Mosconi, Matthew W. ;

Jacob, Suma ;

Cook, Edwin H. .

PHARMACOGENETICS AND GENOMICS, 2015, 25 (11) :548-554

[10] Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder [J].

Biswas, Mohitosh ;

Vanwong, Natchaya ;

Sukasem, Chonlaphat .

PHARMACOGENOMICS, 2022, 23 (08) :493-503

← 1 2 3 4 5 6 7 8 9 →